Ministry of Strategic Industries presents FP-1 long-range drone flying up to 1600 km
Source: Mezha, a technology and IT news platform within Ukrainska Pravda's holding company
Details: Information displayed at the stand indicates that the FP-1 drone is designed to strike enemy targets at strategic depth. It can carry a warhead of up to 120 kilograms and has a range of up to 1,600 kilometres. The weight of the warhead likely affects the maximum flight distance.
Long-range FP-1 drone
"This drone is already being produced in very large volumes, and there is considerable interest from partners. This product was developed in Ukraine and scaled up very quickly. This is another thing we can share with our partners," said Anna Hvozdiar, Deputy Minister of Strategic Industries.
Background: President Zelensky ordered the production of 30,000 long-range drones by 2025 last year. Oboronka reports that the contracting process started in autumn 2024.
Support Ukrainska Pravda on Patreon!
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
4 hours ago
- The Hill
Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash
Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, customers will be able to buy a month's supply of Novo Nordisk's semaglutide pen products for $499 through GoodRx. The list price for a monthly supply of a product like Ozempic is normally around $1,000 or more without insurance. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' GoodRx CEO and President Wendy Barnes said in a statement. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them,' added Barnes. 'It's a powerful example of how the GoodRx platform can deliver savings at scale—bridging gaps in coverage and ensuring more people can get the care they deserve.' This is the most recent in similar moves Novo Nordisk has made to make its popular diabetes and weight loss medication more widely available. Earlier this year, the company announced a direct-to-patient program called NovoCare® Pharmacy for uninsured and underinsured individuals who can pay $499 a month for Wegovy. Novo Nordisk also partnered with online telehealth companies like Ro and LifeMD to sell its pens at the same price point. The telehealth company Hims & Hers was also originally included in the partnership, but Novo Nordisk ended it after accusing the company of illegally selling compounded versions of semaglutide. Hims & Hers maintains it is providing personalized, compounded products within regulatory guidelines. 'Improving access to effective FDA-approved treatment is central to our mission, and our collaboration with GoodRx allows us to reach those who seek savings and support from their trusted and established platform,' Dave Moore, executive vice president of U.S. operations of Novo Nordisk, said in a statement. 'This initiative enables us to meet GoodRx patients where they are with our authentic GLP-1 medicines in addition to supporting the launch of the new Ozempic® self-pay offer for type 2 diabetes patients at an unprecedented price.' Sen. Bernie Sanders (I-Vt.), a prominent critic of high drug costs, called the announcement a 'modest step forward.' 'Novo Nordisk's move to cut the price of Ozempic to $499 for the uninsured is a modest step forward, but let's not forget,' Sanders said on the social media platform X. 'Ozempic costs just $59 in Germany while it costs less than $5 to make. The U.S. must no longer pay the highest prices in the world for prescription drugs.
Yahoo
4 hours ago
- Yahoo
Meta's reported shake-up, Hims & Hers sinks on GoodRx–Novo deal
Meta (META) stock is dipping on reports that the company is restructuring its artificial intelligence (AI) unit for the fourth time in six months, according to The Information. Hims & Hers (HIMS) stock sinks following Novo Nordisk's (NVO) new partnership with GoodRx (GDRX), replacing a scrapped Hims deal back in June. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. It's time for Yahoo! Finance's Market Minute. Stocks little changed ahead of a busy week on Wall Street. Investors are awaiting news from President Trump's meeting with Ukraine's President Zelensky, retail earnings, and the Fed's Jackson Hole Symposium. Meta shares are edging lower by over 2%, underperforming the other Magnificent Seven. The company is planning its fourth restructuring of its AI unit in six months. That's according to a report from The Information. This comes as Meta faces backlash over policies that reportedly allow its AI chatbots to have inappropriate conversations with children. Meanwhile, Hims & Hers shares slumping after Novo Nordisk announced a partnership with GoodRx. Remember, Novo scrapped its deal with Hims in June over what it said were deceptive marketing of compounded versions of Novo Nordisk's weight loss drugs. GoodRx CEO telling Yahoo! Finance today that they have no interest in compounded drugs. And that's your Yahoo! Finance Market Minute. Scan the QR code below to track the best and worst performing stocks of the session.
Axios
5 hours ago
- Axios
Colorado lawmakers tap reserve, end tax breaks to fill budget gap
Democratic leaders at the state Capitol outlined plans Tuesday to increase taxes, cut services and tap reserve funds to close a $1 billion budget hole spurred by President Trump's "big, beautiful bill." State of play: The legislation will generate fierce debate about how the state should manage its money when lawmakers return Thursday for a special legislative session. The core of the Democratic plan eliminates a handful of corporate tax breaks worth a combined $300 million to $400 million. The five-bill package will limit the business tax deduction, remove corporate tax breaks on foreign-sold goods and crack down on corporate profit shifting to tax haven countries. The intrigue: The most controversial proposal is lowering the state's 15% financial reserve by $200 million to $300 million, dropping it to 13% at a time when fiscal analysts are warning about a potential recession. Yes, but: Those moves are not enough to close a roughly $750 million gap. Instead, lawmakers will punt $300 million in spending cuts to balance the $44 billion state budget to the governor in consultation with the legislative Joint Budget Committee in the coming weeks. The governor is expected to move quickly to implement cuts by Sept. 1. What they're saying: "We're looking forward to rolling up our sleeves and making sure we can maintain strong fiscal stewardship here in Colorado," Gov. Jared Polis told Axios Denver in a recent interview. Between the lines: More than most states, Colorado is susceptible to changes in federal taxes because they affect state income taxes. The federal tax bill, known as H.R. 1, reduced the state's individual and corporate income taxes by an estimated $1.2 billion, according to the governor's office. The other side: Republican state lawmakers are touting the cuts from Trump's tax bill and pushing back against Democratic efforts to generate new tax revenue, suggesting spending cuts are what is most needed. Sen. Byron Pelton (R-Sterling) plans to introduce legislation requiring voter approval for any bill that changes state tax liability caused by federal tax law. What's next: Beyond the budget, Democratic lawmakers also plan to introduce legislation to stabilize the state's health care marketplaces amid projections that thousands of residents could lose their insurance and enable Planned Parenthood to accept Medicaid payments.
